The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights From 2008

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 23, Issue 1, 2009, Pages 1-7

  Augoustides, John G T ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

annual highlights; aprotinin; blood transfusions; cardiothoracic anesthesia; clevidipine; coronary stents; cyclosporine; hemoglobin levels; levosimendan; platelet resistance; preconditioning; sodium nitroprusside; transcatheter valves; vascular anesthesia

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; APROTININ; CLEVIDIPINE; CYCLOSPORIN; GLYCERYL TRINITRATE; HEMOGLOBIN; LEVOSIMENDAN; NICARDIPINE; NITROPRUSSIDE SODIUM; TRANEXAMIC ACID;

ANESTHESIA; DRUG DOSE TITRATION; HEART SURGERY; HEART VALVE REPLACEMENT; HUMAN; HYPERTENSION; ISCHEMIC PRECONDITIONING; PERCUTANEOUS CORONARY INTERVENTION; PEROPERATIVE CARE; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANESTHESIA; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; HUMANS; ISCHEMIC PRECONDITIONING; POSTOPERATIVE COMPLICATIONS; THORACIC SURGICAL PROCEDURES; VASCULAR SURGICAL PROCEDURES;

EID: 58149517982     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2008.11.003     Document Type: Review

References (42)

1. Mangano D.T., Tudor J.C., Dietzel C., and Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
2. Brown J.R., Birkmeyer N.J.O., and O'Connor G.T. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 115 (2007) 2801-2813
3. Henry D.A., Carless P.A., Moxey A.J., et al. Antifibrinolytic use for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 4 (2007) CD001886
4. Fergusson D., Glass K.C., Hutton B., et al. Randomized controlled trials of aprotinin in cardiac surgery: Could clinical equipoise have stopped the bleeding?. Clin Trials 2 (2005) 218-230
5. Augoustides J.G., and Fleisher L.A. Comment on: Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: Could clinical equipoise have stopped the bleeding?. Clin Trials 2 (2005) 231-232
6. Fergusson D.A., Hebert P.C., Mazer C.D., et al., BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358 (2008) 2319-2331
7. Ray W.A., and Stein C.M. The aprotinin story-Is BART the final chapter?. N Engl J Med 358 (2008) 2398-2400
8. Augoustides J.G. Perioperative safety of aprotinin in coronary artery bypass graft surgery: Is there life after BART?. Drug Saf 31 (2008) 557-560
9. Kluth M., Lueth J.U., Zittermann A., et al. Safety of low-dose aprotinin in coronary artery bypass graft surgery: A single-centre investigation in 2, 436 patients in Germany. Drug Saf 31 (2008) 617-626
10. Shaw A.D., Stafford-Smith M., White W.D., et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 358 (2008) 784-793
11. Schneeweiss S., Seeger J.D., Landon J., et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 358 (2008) 771-783
12. Ferguson T.B. Aprotinin-Are there lessons learned?. JAMA 297 (2007) 527-529
13. Ray W.A. Learning from aprotinin-mandatory trials of comparative efficacy and safety needed. N Engl J Med 358 (2008) 840-842
14. Sundt T.M. The demise of aprotinin: Our share of the blame. J Thorac Cardiovasc Surg 135 (2008) 729-731
15. Myles P.S. Aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 359 (2008) 1181
16. Myles P.S., Smith J., Knight J., et al. Aspirin and tranexamic acid for coronary artery surgery (ATACAS) trial: rationale and design. Am Heart J 155 (2008) 224-230
17. Pollack C.V., Varon J., Garrison N.A., et al. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med (2008) June 4 [Epub ahead of print]
18. Singla N., Warltier D.C., Gandhi S.D., et al. Treatment of acute postoperative hypertension in cardiac surgery patients: An efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized double-blind, placebo-controlled trial. Anesth Analg 107 (2008) 59-67
19. Aronson S., Dyke C.M., Stierer K.A., et al. The ECLIPSE trials: Comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg 107 (2008) 1110-1121
20. Walsh S.R., Tang T.Y., Kullar P., et al. Ischaemic preconditioning during cardiac surgery: Systematic review and meta-analysis of perioperative outcomes in randomized clinical trials. Eur J Cardiothorac Surg (2008) Sep 8 [Epub ahead of print]
21. Wang L., Ola N., Tropak M., et al. Remote ischemic preconditioning elaborates a blood-borne mediator that protects mitochondrial structure and function and preserves myocardial performance after neonatal cardioplegic arrest. J Thorac Cardiovasc Surg 136 (2008) 335-342
22. Piot C., Croisille P., Staat P., et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359 (2008) 473-481
23. Cavolli R., Kaya K., Aslan A., et al. Does sodium nitroprusside decrease the incidence of atrial fibrillation after myocardial revascularization: A pilot study?. Circulation 118 (2008) 476-481
24. Meyer K., Schipke J.D., Klocke R.C., et al. Inotropic, vasodilating and preconditioning actions of levosimendan in the heart. Thorac Cardiovasc Surg 56 (2008) 379-385
25. Osthaus W.A., Boethig D., Winterhalter M., et al. First experience with intraoperative levosimendan in pediatric cardiac surgery. Eur J Pediatr (2008) Sep 24 [Epub ahead of print]
26. Koch C.G., Liang L., Sessler D.I., et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 358 (2008) 1229-1239
27. Benjamin R.J., and Dodd R.V. Red-cell storage and complications of cardiac surgery. N Engl J Med 358 (2008) 2840-2841
28. Hall S.W. Red-cell storage and complications after cardiac surgery. N Engl J Med 358 (2008) 2841
29. Frenzel T., Sibrowski W., and Westphal M. Red-cell storage and complications after cardiac surgery. N Engl J Med 358 (2008) 2841
30. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: An updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology 105 (2006) 198-208
31. Karkouti K., Wileysundera D.N., Yau T.M., et al. The influence of baseline hemoglobin concentration on tolerance of anemia in cardiac surgery. Transfusion 48 (2008) 666-672
32. Descoutures F., Himbert D., Lepage L., et al. Contemporary surgical or percutaneous management of severe aortic stenosis in the elderly. Eur Heart J 29 (2008) 1410-1417
33. Walther T., Falk V., Borger M.A., et al. Minimally invasive transapical beating heart aortic valve implantation-Proof of concept. Eur J Cardiothorac Surg 31 (2007) 9-15
34. Lozonschi L., Quaden R., Edwards N.M., et al. Transapical mitral valve stent implantation. Ann Thorac Surg 86 (2008) 745-748
35. Kempfert J., Blumenstein J.M., Borger M.A., et al. Minimally invasive off-pump valve-in-a-valve implantation: The atrial transcatheter approach for re-operative mitral valve replacement. Eur Heart J 29 (2008) 2382-2387
36. Walther T., Kempfert J., Borger M.A., et al. Human minimally invasive off-pump valve-in-a-valve implantation. Ann Thorac Surg 85 (2008) 1072-1073
37. Garay F., Webb J., and Hijazi Z.M. Percutaneous replacement of pulmonary valve using the Edwards-Cribier percutaneous heart valve: First report in a human patient. Catheter Cardiovasc Interv 67 (2006) 659-662
38. Orniston J.A., Serruys P.W., Regar E., et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): A prospective open-label trial. Lancet 371 (2008) 899-907
39. Windecker S., Serruys P.W., Wandel S., et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (Leaders): A randomized, non-inferiority trial. Lancet 372 (2008) 1163-1173
40. Krasopoulos G., Brister S.J., Beattie W.S., et al. Aspirin "resistance" and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ 336 (2008) 195-198
41. Price M.J., Endemann S., Gollapudi R.R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000
42. Gori A.M., Marcucci R., Migliorini A., et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 52 (2008) 734-739